Quest Diagnostics stock edges lower after insider sale and UBS target hike

Quest Diagnostics Incorporated (ISIN US74834L1008) stock is trading around USD 235 in early September 2026 on the New York Stock Exchange after a reported insider sale and a solid recent earnings performance that showed revenue of USD 3.04 billion and earnings per share of USD 3.12 for the latest reported quarter, up 10.2 percent and 19.1 percent year over year respectively, according to Zacks data cited on September 8, 2026.

Insider sale and UBS price target adjustment

According to Ad-hoc-news on September 9, 2026, Quest Diagnostics stock recently reacted to a reported insider sale but remained supported by strong profit growth, with the latest quarterly figures showing revenue of USD 3.04 billion and earnings per share of USD 3.12 for the most recently reported quarter, representing increases of 10.2 percent in revenue and 19.1 percent in EPS compared with the same quarter a year earlier.

As Benzinga reported on September 8, 2026, UBS maintained its Neutral rating on Quest Diagnostics stock and raised its price target from USD 232.00 to USD 245.00, implying a target that sits slightly above the current trading band and reflecting cautious optimism about the company’s earnings trajectory and risk profile.

Price level, trading range and valuation context

In a recent price overview, Ad-hoc-news cites data from The Motley Fool showing that Quest Diagnostics shares traded in a short-term band between USD 231.52 and USD 237.56, with a 52-week range from USD 171.18 to USD 247.19, placing the current price area only moderately below the 52-week high and clearly above the 52-week low.

The same overview lists a recent price of USD 235.50 with a daily change of minus 0.69 percent, corresponding to a decline of USD 1.64 on that trading day, indicating that Quest Diagnostics stock softened slightly after the insider transaction but continued to trade well above its 52-week low of USD 171.18 as of the cited period in early September 2026.

According to the corporate-news summary on Ad-hoc-news, Quest Diagnostics stock had a market capitalization of about USD 26.5 billion as of September 2, 2026, at a price of USD 235.50, underscoring the company’s position as a large-cap diagnostics provider with meaningful weight in the health care sector.

Analyst consensus and risk considerations

As MarketBeat noted on September 9, 2026, UBS Group raised its target price on Quest Diagnostics shares from USD 232.00 to USD 245.00 and assigned a Neutral rating, while JPMorgan Chase & Co. previously increased its price target from USD 220.00 to USD 250.00 in a report dated July 28, giving the stock a Neutral rating as well and signaling a broadly similar stance among major banks.

The same MarketBeat article indicates that one analyst currently has a Strong Buy rating, five analysts rate Quest Diagnostics stock as Buy and seven rate it as Hold, resulting in a consensus rating of Moderate Buy and a consensus price target of USD 236.31, which is close to the recent trading level around USD 235.50 and suggests limited upside in the near term if earnings progress in line with expectations.

In addition, GuruFocus highlights that Quest Diagnostics shares around a price of USD 236.74 are considered modestly overvalued relative to a GF Value estimate of USD 195.98, implying about 20.8 percent overvaluation in that framework and underlining valuation risk if growth or margins were to disappoint.

Stock level and investor perspective

With Quest Diagnostics stock trading near USD 235.50 on the NYSE in early September 2026, roughly USD 11.69 below the cited 52-week high of USD 247.19 and more than USD 60 above the 52-week low of USD 171.18, investors see a share price that reflects the recent double-digit revenue and earnings growth while already pricing in a significant portion of the anticipated performance, making future guidance and margin trends key for the next move in the stock.

More news and analyses on Quest Diagnostics stock